Skip to content

Psilocybin research published in 2023

Page 4 of 19: studies 61 to 80 of 375, newest first. Back to the psilocybin overview

Studies

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.

South African Medical Journal November 6, 2023 J Van Der Walt, R Parker 3 citations

Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional experience, and the current approach to managing people in chronic pain often fails to meet the needs of these patients. Novel ways of treating people who suffer from chronic nociplastic pain with classic psychedelic agents may offer a new lens...

DOI: 10.7196/samj.2023.v113i11.814 (opens in new tab) Full text (opens in new tab) Psychedelics Chronic pain treatment Alternative medicine Pain management

Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland

Læknablaðið November 3, 2023 Ragnar Olafsson, Karól Kvaran, Kristín Ketilsdóttir et al. 5 citations

INTRODUCTION: Interest in the use of psychedelics has increased following reports of their possible therapeutic potential. However, little is known about the knowledge of and attitudes towards the substances among health care professional who provide treatment for mental disorders in Iceland. An online survey was therefore conducted among members of the Icelandic associations of psychiatrists,...

Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports

Journal of Psychoactive Drugs November 3, 2023 Marija Franka Žuljević, Antonija Mijatović, Stjepan Ljudevit Marušić et al. 6 citations

Analyzing online retrospective experience reports of psychedelic use can provide valuable insight into their acute subjective effects. Such reports are unexplored in relation to mystical states, which are thought to be a therapeutic mechanism within psychedelic-assisted psychotherapy. We created a set of words that, when encountered in an experience report, indicate the occurrence of mystical...

DOI: 10.1080/02791072.2023.2274382 (opens in new tab) Psilocybin Experience reports Language analysis Mystical states +8

Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms

Addiction November 2, 2023 Celia J. A. Morgan 1 citation

Given the shifting public perception of psilocybin and associated legal changes, the increase in use observed by Keyes and Patrick is not surprising. The conclusion that this is a rising health concern is not justified by the data, particularly as in this sample non-lysergic acid diethylamide hallucinogen use seems to have increased in a white, educated, relatively higher socio-economic status...

Cultivation, chemistry, and genome of Psilocybe zapotecorum

bioRxiv (Cold Spring Harbor Laboratory) November 2, 2023 Jordan Taylor Jacobs, Alan Rockefeller, Harte Singer et al. 4 citations preprint

Abstract Psilocybe zapotecorum is a strongly blue-bruising psilocybin mushroom used by indigenous groups in southeastern Mexico and beyond. While this species has a rich history of ceremonial use, research into its chemistry and genetics have been limited. Herein, we detail mushroom morphology and report on cultivation parameters, chemical profile, and the full genome sequence of P. zapotecorum...

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.

Neuropsychopharmacology November 1, 2023 Daniel Ryskamp Rijsketic, Austen B Casey, Daniel A. N. Barbosa et al. 49 citations

The effects of context on the subjective experience of serotonergic psychedelics have not been fully examined in human neuroimaging studies, partly due to limitations of the imaging environment. Here, we administered saline or psilocybin to mice in their home cage or an enriched environment, immunofluorescently-labeled brain-wide c-Fos, and imaged iDISCO+ cleared tissue with light sheet...

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.

Neuroscience & Biobehavioral Reviews November 1, 2023 Sophia Linguiti, Jacob W Vogel, Valerie J Sydnor et al. 15 citations

Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. While fMRI is a promising tool for measuring brain function in response to psychedelics, it also has known methodological challenges. We conducted a systematic review of fMRI studies examining acute responses to experimentally administered psychedelics...

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Psychiatry Research November 1, 2023 Sipan Haikazian, David C J Chen-Li, Danica E. Johnson et al. 121 citations

The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome...

[Determination of amanita peptide and tryptamine toxins in wild mushrooms by high performance liquid chromatography-tandem mass spectrometry].

Se pu = Chinese journal of chromatography November 1, 2023 Lei-Qi Liu, Jing-Ze Chen, Wu-Sheng Fu et al.

The discovery and identification of mushroom toxins has long been an important area in the fields of toxicology and food safety. Mushrooms are widely favored for their culinary and medicinal value; however, the presence of potentially lethal toxins in some species poses a substantial challenge in ensuring their safe consumption. Therefore, the development of a robust and sensitive analytical...

The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience

Network Neuroscience November 1, 2023 Juan Carlos Farah, Pablo Mallaroni, Enrico Amico et al. 21 citations

Abstract The emerging neuroscientific frontier of brain fingerprinting has recently established that human functional connectomes (FCs) exhibit fingerprint-like idiosyncratic features, which map onto heterogeneously distributed behavioral traits. Here, we harness brain-fingerprinting tools to extract FC features that predict subjective drug experience induced by the psychedelic psilocybin....

The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies

Journal of Psychopharmacology October 31, 2023 Kurt Stocker, Matthias Hartmann, Laura Ley et al. 22 citations

Background: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Experience Questionnaire (MEQ)). The psychometric potential of the non-MEQ items of the PES remains largely unexplored. Aims: We investigated whether the PES also yields subscales besides the MEQ30 subscales. Methods: Data from 239 PES measurements (140...

DOI: 10.1177/02698811231199112 (opens in new tab) Psilocybin Mysticism Psychometrics Exploratory factor analysis +3

Single dose of psilocybin improves depressive symptoms in Phase 2 study

The Brown University Psychopharmacology Update October 30, 2023

A single 25‐mg dose of psilocybin administered with psychological support led to significant and sustained improvement in depressive symptoms compared with placebo in a Phase 2 study of patients with major depressive disorder. A higher number of adverse events occurred in the psilocybin group, but no serious treatment‐emergent adverse events were reported. Study results were published online...

The Psychedelic Social Club: a regulatory concept for people who use psychedelics?

Drugs Education Prevention and Policy October 30, 2023 Henry Harder, Fabian P. Steinmetz, Maja Kohek 3 citations

Background The global drug control landscape is undergoing remarkable change. Many jurisdictions around the world, including jurisdictions in the United States, have decriminalized the possession and use of plant- and fungus-based psychedelics, such as psilocybin-containing mushrooms (PCM). With ORS 475 A, Oregon has gone a step further by becoming the first US state to legalize and regulate...

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review

Annals of Pharmacotherapy October 30, 2023 Dana Kaminski, Justin P. Reinert 21 citations

Objective: The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions. Data sources: A systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: “psilocybin” AND “mental-disease” OR “substance-dependence”...

DOI: 10.1177/10600280231205645 (opens in new tab) Psilocybin Tolerability Hallucinogen Substance use

Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’

Deleuze and Guattari Studies October 27, 2023 Patricia Kubala 6 citations

This paper argues that practitioners of psychedelic-assisted therapy could learn a great deal from Deleuze and Guattari’s critique of psychoanalysis in Anti-Oedipus, as well as the practice of materialist psychiatry – schizoanalysis – that they offer in its stead. Much of the clinical research on psychedelics (particularly psilocybin) over the past fifteen years has privileged mystical...

High-Performance Liquid Chromatography Analysis of Psilocybin-Containing Mushrooms: Key Considerations and Insights

October 26, 2023 Dom Annunziato

HPLC analysis of psilocybin-containing mushrooms is a complex process that requires careful attention to detail. In this scientific summary, Doma Nunzio1, MagicMyco C.S.O., offers insight and new answers to some old questions about these magic fungi. Based on his dedicated research and progress in the field, here are his top five things to keep in mind when conducting HPLC-UV analysis in...

DOI: 10.61073/gentech.hplc.top.5 (opens in new tab) Psilocybin Magic telescope High-performance liquid chromatography Key lock +1

Extended difficulties following the use of psychedelic drugs: A mixed methods study

PLoS One October 24, 2023 Jules Evans, Oliver Robinson, Eirini K. Argyri et al. 166 citations

Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively unexplored in psychedelic research. Our convergent mixed-method study gained quantitative and qualitative data from 608 participants who reported extended difficulties following psychedelic experiences. Data was gathered on the context of use, the nature and duration of the...

Cardiovascular safety of psychedelic medicine: current status and future directions

Pharmacological Reports October 24, 2023 Agnieszka Wsół 56 citations

Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and...

Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms

bioRxiv (Cold Spring Harbor Laboratory) October 23, 2023 Ryan J. Rakoczy, Grace N. Runge, Abhishek K. Sen et al. preprint

ABSTRACT Demand for more efficacious antidepressants, particularly those with a rapid onset of action, has resulted in a reevaluation of psychedelic drugs for their therapeutic potential. Several tryptamines found in psilocybin-containing ‘magic’ mushrooms share chemical similarities with psilocybin, and early work suggests they may also share receptor targets. However, few studies have...